Citigroup cuts Acumen Pharmaceuticals to Neutral and lowers target to $1
Citigroup downgraded Acumen Pharmaceuticals to Neutral from Buy and cut its price target to $1 from $5. Data via TradingView, citing Benzinga.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Citigroup has moved its rating on Acumen Pharmaceuticals to Neutral from Buy and reduced the price target to $1 from $5, a cut of 80.0%. According to TradingView, citing data from Benzinga, the new target implies a 376.0% gain from the October 30 close of $0.21.
This is a single analyst action on a low-priced stock, and the figures describe the target itself rather than any expected outcome. The material is for general information only and is not an investment recommendation.
why it matters
For the broader market this is a company-specific event with little read-across to indices or the biotech sector. It mainly matters to holders of the stock, who now face a major brokerage with a neutral stance and a sharply lower valuation anchor.
tags
instruments
sources
- Citigroup downgrades Acumen Pharmaceuticals to Neutral from Buy, lowers price target to $1 from $5 — TradingView, 30 October 2026 at 20:33 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗